Share This Page
BECONASE AQ Drug Patent Profile
✉ Email this page to a colleague
When do Beconase Aq patents expire, and when can generic versions of Beconase Aq launch?
Beconase Aq is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in BECONASE AQ is beclomethasone dipropionate monohydrate. Additional details are available on the beclomethasone dipropionate monohydrate profile page.
US Patents and Regulatory Information for BECONASE AQ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | BECONASE AQ | beclomethasone dipropionate monohydrate | SPRAY, METERED;NASAL | 019389-001 | Jul 27, 1987 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
BECONASE AQ (beclomethasone dipropionate) investment scenario and patent/IP fundamentals analysis
BECONASE AQ is a beclomethasone dipropionate (BDP) intranasal corticosteroid with mature commercial status and a long history of generic availability pressure. For an investment case focused on R&D novelty, licensing leverage, or late-stage entry economics, the key IP question is whether any remaining U.S. Orange Book–listed patents still constrain generic or authorized generic entry for the approved dosage form, strengths, and labeling-controlled indications. On the fundamentals side, demand durability is supported by chronic allergic rhinitis use, but unit growth is capped by established generic competition and pharmacy substitution dynamics.
What this analysis covers: U.S. IP posture as it relates to BECONASE AQ, expected exclusivity/patent timelines, formulation and method-of-use risk areas that can still matter for a generic challenge, biosimilar relevance, FDA and Orange Book status, and a practical competitive and litigation framework for investors.
What this analysis does not cover: No product-specific patent and Orange Book data is provided in the prompt, and no external record lookups are available in this environment. Without the exact Orange Book listing identifiers (application numbers, patent numbers, expiration dates, exclusivity codes), a complete, accurate patent-expiration timeline and litigation map for BECONASE AQ cannot be produced.
What patents protect BECONASE AQ (beclomethasone dipropionate) in the US?
Answer needed for investment-grade diligence: Which Orange Book patents are listed for the specific BECONASE AQ NDA and which of those patents are still unexpired as of the investment decision date. This determines whether generic entry is blocked by composition, formulation, device, or method-of-use IP.
Which patent types typically matter for an intranasal corticosteroid like beclomethasone dipropionate?
For established intranasal steroids, enforceable barriers most often come from:
- Formulation/device patents tied to particle size distribution, suspension stability, spray characteristics, droplet formation, or preservative systems.
- Method-of-use patents covering dosing regimens or specific patient subsets (less common for entrenched rhinitis products once labeling broadens).
- Process/manufacturing patents (conversion, micronization, solvent handling) where generics can design around but may face evidentiary disputes.
How many patents cover BECONASE AQ?
A numeric count requires Orange Book patent listing data for the exact product. That data is not present in the prompt, so a reliable number cannot be stated.
When does BECONASE AQ lose exclusivity and when do patents expire?
Answer needed for investment-grade diligence: The latest expiration date among:
- U.S. Orange Book listed patents tied to the marketed product.
- Any applicable regulatory exclusivity (3-year, 5-year, pediatric exclusivity extensions) if they attach to the relevant regulatory milestones.
Typical exclusivity timeline mechanics
For older corticosteroid intranasals, most value is generally time-discounted by:
- Expired primary composition and basic formulation patents.
- Residual barriers limited to niche formulation/process claims, or to narrow method-of-use claims that track specific labeling language.
But without the Orange Book listing set for BECONASE AQ, the expiration timeline cannot be stated accurately.
What generic entry risks exist for BECONASE AQ (Paragraph IV and design-around)?
Answer needed for investment-grade diligence: Whether any current or prospective generic applicants have filed ANDAs that include Paragraph IV certifications against specific listed patents for BECONASE AQ, and whether litigation resulted in:
- a 30-month stay,
- a consent judgment,
- a settlement carve-out that delays entry, or
- an up-front finding of non-infringement/invalidity.
Paragraph IV risk framework investors actually underwrite
- Near-term bottlenecks: patents with expiration in the next 0 to 36 months plus any pediatric extensions.
- Long-tail bottlenecks: formulation or method-of-use patents that can survive even when older composition IP is gone.
- Design-around feasibility: whether a generic can reformulate (suspension characteristics, spray plume profile) while meeting bioequivalence.
A reliable assessment requires the list of Orange Book patents that are still in-force and the procedural history of any ANDA/P-IV activity.
What is the Orange Book status of BECONASE AQ right now?
Answer needed for investment-grade diligence: The current Orange Book status requires the NDA number(s) and listed patent numbers with their status (Expired, Active, Expiration date) and exclusivity type.
Without that listing, any statement about “active patents remaining” would be speculative, which is not acceptable for high-stakes investment diligence.
What Orange Book metadata matters most for business decisions?
- NDA/application number linkage to ensure the correct marketed configuration.
- Patent expiration dates for the last-to-expire patent(s).
- Exclusivity code(s) that may extend market protection beyond the last listed patent.
- Reference drug product category that affects which generic submissions can rely on which labeling.
What formulations are protected by BECONASE AQ patents?
Answer needed for investment-grade diligence: Without the remaining patent corpus, it is not possible to identify protected formulation concepts (suspension chemistry, surfactant system, micronization specification, droplet size target, valve/spray actuator design).
Investor-relevant formulation claim hotspots
For intranasal corticosteroids, formulation IP often clusters around:
- Particle size and distribution affecting deposition in nasal mucosa.
- Rheology and suspension uniformity controlling dosing consistency through storage.
- Preservative and excipient system minimizing microbial growth while maintaining spray performance.
- Device-drug interaction such as actuator geometry that shapes the spray cone.
These are the claim themes investors should test against the actual patent claims in force.
What method-of-use patents protect BECONASE AQ dosing or indications?
Answer needed for investment-grade diligence: Method-of-use patents must be identified by claim scope and their relationship to current labeling.
How method-of-use protection affects generic and authorized generic economics
Method-of-use barriers can matter even after formulation patents expire if:
- The labeling for allergic rhinitis or other conditions tracks the protected dosing regimen.
- Generic labels require FDA labeling carve-outs to avoid infringement.
But the specific method-of-use patent landscape cannot be mapped without Orange Book listing details.
What FDA regulatory status does BECONASE AQ have, and does it support lifecycle extensions?
Answer needed for investment-grade diligence: FDA status details include:
- NDA approval details and labeling evolution.
- Changes to formulation (if any), strengths, or device.
- Whether any recent supplemental approvals could have attached exclusivity.
The prompt does not contain FDA regulatory history or NDA identifiers.
Pathway relevance for competition
For generics:
- ANDA pathway typically supports systemic generic manufacturing of an intranasal steroid with bioequivalence approaches. For authorized generics:
- Exclusivity can be circumvented through licensing, not by regulatory pathway.
Which companies are challenging BECONASE AQ, and what patent litigation affects entry?
Answer needed for investment-grade diligence: A litigation map requires:
- ANDA filer names,
- Paragraph IV filing dates,
- court docket outcomes,
- settlement terms, and
- the set of patents asserted.
None of that data is provided in the prompt.
How to interpret litigation outcomes for an investment case
- Early dismissals shift the economic window to generic launch.
- Settlements can create a predictable pay-for-delay schedule.
- Adverse decisions can accelerate authorized generic or multiple ANDA launches.
How does BECONASE AQ compare with other beclomethasone dipropionate nasal sprays on IP and competition?
Answer needed for investment-grade diligence: Comparison requires the specific comparator list (for example, other BDP intranasal products), each product’s Orange Book patent stack, and their labeled indications.
A cross-product comparison cannot be produced without at least one comparator’s Orange Book listing set and the exact product configuration of BECONASE AQ.
Is BECONASE AQ exposed to biosimilar risk?
Answer: No. BECONASE AQ is a small-molecule corticosteroid (beclomethasone dipropionate) and is not a biologic product. Biosimilar pathways and biosimilar exclusivity do not apply.
Revenue exposure: what does generic competition typically do to BECONASE AQ economics?
Investment signal investors should underwrite For mature, OTC-adjacent or chronic symptomatic therapies with entrenched generics:
- pricing compresses quickly after generic entry,
- volume can remain resilient but margins contract,
- pharmacy channel substitution is strong because clinical differentiation is limited.
The investable question becomes whether remaining IP supports:
- differentiated formulation/delivery,
- device-based advantages,
- or labeling exclusivity for a sub-indication that supports premium pricing.
Without the current patent stack and exclusivity timelines, an investment-grade forecast of pricing durability cannot be stated.
Commercial timeline scenario for BECONASE AQ (generic entry and market erosion)
A practical scenario model requires:
- last-to-expire U.S. protection date,
- whether any Paragraph IV litigation is ongoing,
- and whether any settlements delay generic launches.
Since those inputs are absent, only the structural model can be described, not a date-specific forecast:
- If no unexpired Orange Book patents remain, generic launches tend to cluster around the earliest permissible date for ANDA approvals and patent-expiration windows.
- If formulation or method-of-use patents remain active, generic labels and launches can be delayed by carve-outs or litigation.
Key Takeaways
- BECONASE AQ is a mature small-molecule intranasal corticosteroid; biosimilar risk is not applicable.
- The investment-critical determinant is the remaining U.S. Orange Book patent stack for the exact BECONASE AQ NDA: which patents remain active, their expiration dates, and whether any current Paragraph IV challenges or settlements constrain generic launch.
- Demand durability from allergic rhinitis use may support volume stability, but economic upside depends on whether enforceable IP still protects premium pricing or market share.
- A date-specific exclusivity and litigation scenario cannot be completed from the provided prompt because Orange Book listing identifiers, patent numbers, expiration dates, and litigation records are not included.
FAQs
- Does BECONASE AQ have Orange Book-listed exclusivity beyond patent expiry?
- How do method-of-use patents affect generic labeling for beclomethasone dipropionate nasal sprays?
- What evidence do generic applicants use to challenge intranasal corticosteroid formulation patents?
- Can authorized generics enter before all Orange Book patents expire for BECONASE AQ?
- What non-patent barriers (REM S issues, manufacturing controls, device QA) can slow generic entry for intranasal sprays?
References (APA)
- (No citable sources provided in the prompt.)
More… ↓
